Extrawell Pharmaceutical Holdings Limited operates as an investment holding enterprise, primarily engaged in the creation, production, promotion, and distribution of pharmaceutical solutions across the People's Republic of China and Hong Kong. Its diverse operations are organized into key divisions: Manufacturing, Trading, Gene Development, and a dedicated Oral Insulin segment. Within its manufacturing arm, the company produces a range of specialty drugs, including an oral solution designed as a dual immune regulator for viral infections and weakened cellular immunity, a topical treatment for various skin issues such as radiation burns, general burns, dermatitis, and ulcers, as well as for aiding in post-operative wound recovery, and a compound that inhibits thromboxane synthetase, which helps prevent blood clotting and promotes vasodilation. The trading segment focuses on promoting and distributing a portfolio of imported pharmaceutical items, featuring treatments for hypertension and products addressing a spectrum of skin conditions like itching, redness, and scaly patches, alongside therapies for central nervous system lesions and Parkinson's disease. This division also handles imported healthcare products, nutritional items, and medical equipment, including specific pain management devices and Australian dairy products under its own brand. The gene development division is dedicated to the commercial application and advancement of genomic technologies. Furthermore, the company is actively involved in the clinical trial development of an oral insulin product for diabetes management. Complementing these core activities, Extrawell also provides agency services and maintains interests in property investments. While the company reported a significant profit turnaround for the fiscal year ending March 31, 2025, largely driven by gains from convertible bond fair value changes, it later projected an expected loss for the six months ending September 30, 2025, predominantly due to unrealized losses on similar investments. In a strategic move, Extrawell completed a new share issuance in September 2025 to facilitate diversification into the broader healthcare sector, aligning with national strategies and targeting emerging markets. The corporate headquarters are situated in Quarry Bay, Hong Kong.